Literature DB >> 10485913

Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.

S S Cohen1, C Li, L Ding, Y Cao, A B Pardee, E M Shevach, D I Cohen.   

Abstract

HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with soluble protein (sTat), and in seroconverting humans, and propose that Tat-induced suppression cripples immune surveillance to HIV infection. We show that macrophages are sensitive to sTat stimulation at concentrations 1,000-fold lower (500 pM) than T cells, and this stimulation is accompanied by the immunosuppressive induction of Fas ligand on the macrophage. T cell proliferative defects induced by sTat in vitro can be completely (at lower concentrations of sTat) or partially (at higher concentrations) reversed by antagonists to Fas/Fas ligand interaction. We further report a method to preserve immunogenicity while inactivating Tat immunosuppression through oxidation, which advances the use of oxidized Tat as a component of an anti-HIV vaccine. These observations define additional methods to study the immunosuppressive functions of sTat that now may be rapidly applied to primary isolates from individuals with differing clinical courses. Our findings have immediate relevance for vaccine development, by describing and supporting a strategy that includes inactivated sTat in a multicomponent, anti-HIV vaccine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485913      PMCID: PMC17970          DOI: 10.1073/pnas.96.19.10842

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Human immunodeficiency virus.

Authors:  E A Emini; S D Putney
Journal:  Biotechnology       Date:  1992

2.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.

Authors:  N Itoh; S Yonehara; A Ishii; M Yonehara; S Mizushima; M Sameshima; A Hase; Y Seto; S Nagata
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

3.  Cellular uptake of the tat protein from human immunodeficiency virus.

Authors:  A D Frankel; C O Pabo
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

4.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

5.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Authors:  G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

6.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

7.  Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.

Authors:  J Luban; K L Bossolt; E K Franke; G V Kalpana; S P Goff
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

8.  Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis.

Authors:  N K Banda; J Bernier; D K Kurahara; R Kurrle; N Haigwood; R P Sekaly; T H Finkel
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

9.  Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope.

Authors:  T C Rodman; F H Pruslin; S E To; R Winston
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

10.  Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals.

Authors:  H Groux; G Torpier; D Monté; Y Mouton; A Capron; J C Ameisen
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  21 in total

1.  Tat-neutralizing antibodies in vaccinated macaques.

Authors:  Ilia Tikhonov; Tracy J Ruckwardt; Glen S Hatfield; C David Pauza
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.

Authors:  H Xiao; C Neuveut; H L Tiffany; M Benkirane; E A Rich; P M Murphy; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 3.  Using death to one's advantage: HIV modulation of apoptosis.

Authors:  T M Ross
Journal:  Leukemia       Date:  2001-03       Impact factor: 11.528

4.  Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.

Authors:  Laurent Mascarell; Catherine Fayolle; Cécile Bauche; Daniel Ladant; Claude Leclerc
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice.

Authors:  Ana Toro; Eyal Grunebaum
Journal:  J Clin Invest       Date:  2006-09-07       Impact factor: 14.808

6.  Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway.

Authors:  A Badou; Y Bennasser; M Moreau; C Leclerc; M Benkirane; E Bahraoui
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication.

Authors:  P Secchiero; D Zella; S Curreli; P Mirandola; S Capitani; R C Gallo; G Zauli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

8.  Human immunodeficiency virus-1 tat induces hyperproliferation and dysregulation of renal glomerular epithelial cells.

Authors:  Pier Giulio Conaldi; Antonella Bottelli; Andreina Baj; Caterina Serra; Lisa Fiore; Giovanni Federico; Benedetta Bussolati; Giovanni Camussi
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  Acute HIV-1 infection in the Southeastern United States: a cohort study.

Authors:  Mehri S McKellar; Anna B Cope; Cynthia L Gay; Kara S McGee; Joann D Kuruc; Melissa G Kerkau; Christopher B Hurt; Susan A Fiscus; Guido Ferrari; David M Margolis; Joseph J Eron; Charles B Hicks
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-04       Impact factor: 2.205

10.  Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.

Authors:  Yida Yang; Ilia Tikhonov; Tracy J Ruckwardt; Mahmoud Djavani; Juan Carlos Zapata; C David Pauza; Maria S Salvato
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.